Active, not recruitingPhase 2NCT05798156
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Principal Investigator
- Salah-Eddin Al-Batran, Prof. Dr.Institut fuer Klinische Krebsforschung IKF GmbH
- Intervention
- Glofitamab(drug)
- Enrollment
- 125 enrolled
- Eligibility
- 61 years · All sexes
- Timeline
- 2023 – 2028
Study locations (30)
- Uniklinik Innsbruck, Innsbruck, Austria
- Kepler Universitätsklinikum, Linz, Austria
- Ordensklinikum Linz - Barmherzige Schwestern, Linz, Austria
- Ordensklinikum Linz - Elisabethinen, Linz, Austria
- Landeskrankenhaus Salzburg Universitätsklinikum der Paracelsus Medizinischen Privatuniversität, Salzburg, Austria
- Univ. Klinikum St. Pölten, Sankt Pölten, Austria
- AKH Meduni Wien, Vienna, Austria
- Hanusch Krankenhaus, Vienna, Austria
- Universitätsklinikum Magdeburg, Magdeburg, Saxony-Anhalt, Germany
- Charité - Universitätsmedizin Berlin, Berlin, Germany
- HELIOS Klinikum Berlin-Buch, Berlin, Germany
- Medizinisches Universitätsklinikum Knappschaftskrankenhaus Bochum, Bochum, Germany
- Klinikum Chemnitz, Chemnitz, Germany
- Uniklinikum Düsseldorf, Düsseldorf, Germany
- Universitätsklinikum Erlangen, Erlangen, Germany
- +15 more locations on ClinicalTrials.gov
Collaborators
Charite University, Berlin, Germany · University of Salzburg · Arbeitsgemeinschaft medikamentoese Tumortherapie · Roche Pharma AG · Zentrum für Klinische Studien Leipzig · Hoffmann-La Roche
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05798156 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic